Skip to main content

TOMI Environmental Solutions, Inc. Announces Unaudited Preliminary Financial Results for Q1 2026 Revenue Reflecting Strong Sequential Revenue Growth Over Q4

FREDERICK, Md., April 08, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions is pleased to announce that its preliminary unaudited revenue for the first quarter of 2026 was approximately $1.7 million, reflecting a 67% sequential increase from Q4 2025. Total integrated projects, which encompass projects awaiting capital expenditure approval or signed contracts for our SteraMist Integrated System (SIS), Hybrid, or Custom Engineered System (CES) products have increased to $5.3 million. This pipeline includes 14 customers, with half approved and secured through purchase orders or contracts. To date, first quarter sales combined with current open orders has reached approximately $3,360,000. When compared to Q1 2025 and the previous reporting...

Continue reading

Virco Reports Full Year Net Income of $2.6 Million on Revenue of $199.7 Million

Shareholder Distributions Totaled $5.6 Million, Including $1.6 Million of Dividends and $4.0 Million of Share Repurchases Tight Operating and Financial Controls in Place Current Ratio Remains Healthy at 3.1 Early Order Rates Underscore Normalization of School Furniture MarketTORRANCE, Calif., April 08, 2026 (GLOBE NEWSWIRE) — Virco Mfg. Corporation (NASDAQ: VIRC), a leading manufacturer and supplier of moveable furniture and equipment for educational environments and public spaces, announced results for the Company’s fourth quarter and full fiscal year ended January 31, 2026. For the fourth quarter alone, total revenue was $26.2 million, a decrease of 8.1% from $28.5 million in the same period last year. Operating loss for the quarter was $9.9 million compared to operating loss of $8.1 million in the same period last year. This...

Continue reading

SEALSQ Reports Q1 2026 Key Financial and Operational Metrics and Provides Business Update

Geneva, Switzerland, April 08, 2026 (GLOBE NEWSWIRE) — Reaffirms FY 2026 Revenue Guidance, Projecting Year-Over-Year Growth of 50% to 100%, Underscoring Continued Business Momentum SEALSQ Corp. (NASDAQ: LAES), (“SEALSQ” or “Company”), a leading developer of post-quantum semiconductors and cybersecurity solutions, today announces key financial and operational metrics for Q1 2026 and reaffirms its full-year 2026 financial guidance. All Q1 2026 numbers reported are preliminary and unaudited. SEALSQ ended Q1 2026 with clear commercial momentum, marked by scaled production, accelerated advancements in Post-Quantum innovation, expanding global partnerships, and solidified position as a leader in the emerging quantum-security infrastructure market. Q1 2026 Key Financial and Operational Highlights Q1 2026 revenue...

Continue reading

AXIL Brands, Inc. Reports Third Quarter Fiscal Year 2026 Financial Results

LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) — AXIL Brands, Inc. (“AXIL,” “we,” “us,” “our,” or the “Company”) (NYSE American: AXIL), an emerging global consumer products company for AXIL® hearing protection and enhancement products and Reviv3® hair and skin care products, and marketing services for third-party brands today announced financial and operational results for the third fiscal quarter ended February 28, 2026 (“Q3 2026”). Financial Highlights for the Quarter Ended February 28, 2026Net sales increased 5.4% in Q3 2026 to $7.3 million, compared to $6.9 million in the prior year period Gross profit was largely unchanged at approximately $5.0 million for both periods, representing 69.1% gross margin in Q3 2026, compared to 71.7% in the prior year period Operating expenses of $4.8 million were 66.2% of net sales in Q3 2026,...

Continue reading

GlobalTech Corporation Reports Fiscal Year 2025 Financial Results

GLTK Reports 21% Revenue Growth and Expands AI Platform Commercialization RENO, Nev., April 08, 2026 (GLOBE NEWSWIRE) — GlobalTech Corporation (OTCQB: GLTK) (“GlobalTech” or the “Company”) today announced financial results for the year ended December 31, 2025, as previously reported in its Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 31, 2026. Fiscal Year 2025 HighlightsNet Revenue: $22.1 million, up 21% from $18.3 million in 2024 Operating Loss: $(3.7) million Net Loss: $(3.1) million Adjusted EBITDA: $0.89 million (non-GAAP)* Total Assets: $103.1 million Total Shareholders’ Equity: $39.8 millionRevenue and Operating Performance Revenue growth in fiscal 2025 was driven by continued expansion across GlobalTech’s core operating segments:Telecommunications: 2025 revenue of $17.5...

Continue reading

Loblaw Companies Limited Announces the Timing of the First Quarter 2026 Earnings Release and Annual Meeting of Shareholders

BRAMPTON, Ontario, April 08, 2026 (GLOBE NEWSWIRE) — Loblaw Companies Limited (TSX: L) announced today that it will release its 2026 first quarter results on May 6th, 2026, at approximately 6:30 a.m. (ET). The release will be followed by a conference call at 10:00 a.m. (ET), as well as an audio webcast. To access via audio webcast please go to the “Investor” section of loblaw.ca and note that pre-registration will be available. Alternatively, please dial (647) 932-3411 or Toll-Free (800) 715-9871. Following the live event, the webcast will be archived and available to replay for 12 months. This year the Loblaw Companies Limited Annual Meeting of Shareholders will be held on May 12, 2026, at 10:00 a.m. (ET), at Massey Hall, 178 Victoria Street, Toronto, Ontario, Canada. Shareholders who are not able to attend in person will be able...

Continue reading

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg confirmatory trial for full approval in r/r CLL Targeting 2026 IND submission for bexobrutideg in inflammatory and autoimmune indications with a new tablet formulation Continuing advancement of targeted protein degraders of IRAK4 in Phase 1 and STAT6 in IND-enabling studies under strategic partnerships Well capitalized with $540.7 million on the balance sheet BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today reported financial results for...

Continue reading

Stella-Jones’ First Quarter 2026 Results Conference Call and Annual Meeting of Shareholders

MONTRÉAL, April 08, 2026 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX: SJ), (“Stella-Jones” or the “Company”) will hold a conference call to discuss its first quarter results:  Open to: Investors, analysts and all interested parties  Date: Wednesday, May 6, 2026  Time: 8:00 AM Eastern Daylight Time (EDT)  Live Webcast: https://meetings.lumiconnect.com/400-925-467-567  Call: Local – Toronto: +1 (416) 855-9085 Toll Free – North America: +1 (800) 990-2777 Conference ID: 85640     The press release will be published before market opens the day of the conference call through Globe Newswire. Please log on or dial in 15 minutes before the conference begins. If you are unable to attend at this time, you may access a web recording of the meeting at the following link: https://meetings.lumiconnect.com/400-925-467-567....

Continue reading

Lerøy Seafood Group ASA: Trading update Q1 2026

HARVEST VOLUMES OF SALMON AND TROUT Total harvest volume of salmon and trout for Q1 2026 was 39,900 GWT, compared to 38,200 GWT in Q1 2025. These figures exclude harvest volumes from Scottish Seafarms. Harvest volumes by region for Q1 2026 (Q1 2025), measured in 1,000 GWT:Lerøy Aurora: 8.3 (7.1) Lerøy Midt: 16.0 (16.4) Lerøy Sjøtroll: 15.7 of which 6.1 were trout (14.8 of which 9.5 were trout)CATCH VOLUMES OF WILDFISH Total wild catch volumes in Lerøy Havfisk, measured in 1,000 tonnes:Q1 2026: 14.3 of which 2.7 were cod Q1 2025: 19.0 of which 3.6 were codThe complete Q1 2026 report will be released on 12 May at 06:30 CET. Queries may be addressed to the company’s CFO, Sjur S. Malm. This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Continue reading

Firm Capital Apartment REIT Provides Strategic Review Update, Q4/2025 and 2025 Results

All figures in $USD unless otherwise noted. TORONTO, April 07, 2026 (GLOBE NEWSWIRE) — Firm Capital Apartment Real Estate Investment Trust (“the “Trust”), (TSXV: FCA.U), (TSXV: FCA.UN) is pleased to report its financial results for the three and twelve months ended December 31, 2025 and provide a Strategic Review update: EARNINGS Excluding non-cash fair value adjustments, net income for the three months ended December 31, 2025 was approximately $0.1 million, in line with the $0.1 million net income reported for the three months ended September 30, 2025, and the $0.1 million net income reported for the three months ended December 31, 2024. Excluding non-cash fair value adjustments, for the twelve months ended December 31, 2025, net income was approximately $0.7 million, in comparison to the $0.15 million net loss reported for the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.